15 completed, 9 terminated, 2 recruiting, 2 withdrawn. 21 Phase 2, 15 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 9, Terminated 9, Withdrawn 2, Recruiting 1 |
| Phase 1 | 15 | Completed 7, Terminated 6, Withdrawn 2 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
Follow ganitumab: new trials by email Literature Review of ganitumab trials Research Report on ganitumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice - Metastatic Sarcoma, Recurrent Sarcoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 20 | 2025-02-25 | 2026-08-11 |
| Palbociclib + Ganitumab In Ewing Sarcoma Palbociclib, Ganitumab - Ewing Sarcoma, Ewing's Sarcoma Recurrent | Phase 2 | Terminated | Dana-Farber Cancer Institute | 10 | 2019-12-05 | 2024-08-01 |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma Dasatinib, Ganitumab - Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2017-07-07 | 2022-04-14 |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride - Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 312 | 2014-12-12 | 2026-10-22 |
| A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors BYL719, AMG 479 - PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 47 | 2012-11-27 | 2018-09-13 |
| Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab AMG 479, Trastuzumab - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2012-11-01 | 2016-10-26 | |
| A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors MEK162, AMG 479 - Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma | Phase 1 / Phase 2 | Terminated | Pfizer | 77 | 2012-08-27 | 2020-12-10 |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer ganitumab, fluorouracil, irinotecan hydrochloride - Pancreatic Cancer | Phase 1 / Phase 2 | Withdrawn | Alliance for Clinical Trials in Oncology | 2012-08-01 | 2016-06-28 | |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas Gemcitabine, AMG 479, Placebo - Adenocarcinoma of the Pancreas, Locally Advanced | Phase 2 | Terminated | NantBioScience, Inc. | 10 | 2012-05-31 | 2024-11-08 |
| Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas ganitumab, capecitabine, gemcitabine hydrochloride - Pancreatic Cancer | Phase 1 | Completed | Radiation Therapy Oncology Group | 8 | 2012-02-01 | 2015-11-17 |
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas AMG 479, Placebo, gemcitabine - Adenocarcinoma of the Pancreas, Advanced Solid Tumors | Phase 3 | Completed | NantCell, Inc. | 800 | 2011-04-07 | 2024-07-16 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Modified FOLFOX6, Conatumumab, Ganitumab - Advanced Solid Tumors, Carcinoid | Phase 2 | Completed | Amgen | 12 | 2011-03-03 | 2021-02-21 |
| Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors RAD001 + AMG479 - Neoplasm Metastases | Phase 1 | Completed | Shadia Jalal | 27 | 2010-05-14 | 2017-05-10 |
| A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 AMG 479, Everolimus, Panitumumab - Advanced Solid Tumors, Non-small Cell Lung Cancer | Phase 1 | Completed | Jeffrey Clarke | 43 | 2010-04-01 | 2019-08-28 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
| AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors AMG 479 - Neuroendocrine Tumor, Carcinoid Tumor | Phase 2 | Completed | Dana-Farber Cancer Institute | 60 | 2010-03-01 | 2018-03-08 |
| Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab Panitumumab, Ganitumab, Irinotecan - Metastatic Colorectal Cancer | Phase 2 | Completed | NantBioScience, Inc. | 74 | 2009-05-05 | 2024-07-17 |
| QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma FOLFIRI, AMG 655, Placebo - Metastatic Colorectal Cancer | Phase 2 | Completed | NantCell, Inc. | 155 | 2009-03-01 | 2016-10-27 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors AMG 479, AMG 655 - Colorectal Cancer, Locally Advanced | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 89 | 2009-01-16 | 2024-08-20 |
| QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer AMG 479, Carboplatin, Paclitaxel - Advanced Squamous Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 15 | 2009-01-01 | 2024-09-25 |
Showing 20 of 30. Sign in to see all of them.
Neoplasm Metastasis (6) · Pancreatic Neoplasms (6) · Sarcoma (6) · Colorectal Neoplasms (5) · Breast Neoplasms (4) · Ovarian Neoplasms (4) · Sarcoma, Ewing (4) · Carcinoma, Non-Small-Cell Lung (3) · Insulin-Like Growth Factor I, Resistance To (3) · Neoplasms (3) · Adenocarcinoma (2) · Carcinoid Tumor (2) · Colonic Neoplasms (2) · Lymphoma (2) · Rectal Neoplasms (2)
NantCell, Inc. (9) · NantBioScience, Inc. (3) · Amgen (2) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Translational Research in Oncology (2) · Alliance for Clinical Trials in Oncology (1) · Jeffrey Clarke (1) · Jonsson Comprehensive Cancer Center (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · QuantumLeap Healthcare Collaborative (1) · Radiation Therapy Oncology Group (1) · Shadia Jalal (1)
United States (21) · Spain (9) · Canada (7) · France (6) · Germany (5) · United Kingdom (5) · Belgium (4) · Poland (4) · Australia (3) · Hungary (3) · Ireland (3) · Italy (3) · Russia (3) · Austria (2) · Czechia (2)
Gottfried E Konecny, MD (2) · Brain Wolpin, MD (1) · Christine M Heske, M.D. (1) · Christopher H. Crane, MD (1) · David Shulman, MD (1) · Francisco J. Esteva, MD,PHD (1) · Herbert Hurwitz, MD (1) · Joseph Ludwig, MD (1) · Laura Esserman, MD, MBA (1) · Mace L. Rothenberg, MD, FACP (1) · Matthew Kulke, MD (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 26049686, PMID 27406346, PMID 27406347, PMID 28851423, PMID 28945848, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 36669140, PMID 37029329, PMID 37306107, PMID 37325931, PMID 37398992, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42208702, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224
2008 (1), R01CA180279 (1), U10CA098543 (1), U10CA180886 (1)